We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
14 January 2019
On 1 January 2019 new provisions amending the Patent Act entered into force. While one set of provisions addresses the professional use of pharmaceuticals, the other addresses incentives regarding research and development for paediatric pharmaceuticals.
The revised Patent Act includes two additional exemptions from patent protection that aim to safeguard the professional use of pharmaceuticals in favour of patients:
The revised Patent Act also aims to stimulate R&D for paediatric pharmaceuticals. To this end, patent owners may now request to extend their patent protection for six months if they conduct clinical studies concerning the paediatric use of a pharmaceutical. If such a requirement is met, owners may request either:
Applicants must prove that clinical studies have been conducted in accordance with paediatric examination concepts and that study results are published in the information covering the pharmaceutical. Further, requests cannot be filed more than six months after applying for marketing authorisation in the European Economic Area.
The deadline for filing a request to extend a pre-existing supplementary protection certificate is two years before the certificate expires, while the deadline to request a special paediatric supplementary protection certificate is two years before the patent term expires.
Transitional provisions will apply for five years from 1 January 2019.
For further information on this topic please contact Mathis Berger at Nater Dallafior Rechtsanwälte AG by telephone (+41 44 250 45 30) or email (firstname.lastname@example.org). The Nater Dallafior Rechtsanwälte AG website can be accessed at www.naterdallafior.ch.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.